Annals of Oncology Podcasts

Designed to keep our readers up to date, Annals of Oncology Podcasts are hosted by our Deputy Editor Dan Haller M.D. and feature unique and personal insights into the latest research published in the Journal.

Follow us on Soundcloud or Spotify.


Genome instability and success of checkpoint inhibitors

Dr Sarah Derks, of Amsterdam UMC, discusses her recent editorial in Annals of Oncology on the report of Shitara et al. who presented an exploratory analysis from the KEYNOTE-061 trial evaluating the association of tTMB with PD-L1 and MSI-H and their relationship with clinical outcomes in patients with advanced gastric/GEJ cancer receiving second-line pembrolizumab or paclitaxel.

Read the associated article

Genome instability and success of checkpoint inhibitors

Immunotherapy trials for metastatic triple-negative breast cancer

Dr Marleen Kok, of the Netherlands Cancer Institute, discusses her recent editorial, written with Dr Leonie Voorwerk, on the results of the IMpassion130 and IMpassion131 trials of immunotherapy in unresectable, locally advanced, or metastatic triple-negative breast cancer, results of which are both published in the August issue of Annals of Oncology.

Read the associated article
and
Read the associated article
and
Read the associated article

Immunotherapy trials for metastatic triple-negative breast cancer

IgE blockade in the management of eosinophil-associated recalcitrant pruritus

Professor Ralf Gutzmer, of the Skin Cancer Center Minden, discusss his recent editorial, with colleagues, on a the recently published study of Barrios et al, which sought to evaluate the efficacy and safety of IgE blockade with omalizumab in cancer patients with refractory pruritus-associated cutaneous adverse events related to checkpoint inhibitors and anti-HER2 agents.

Read the associated article
and
Read the associated article

IgE blockade in the management of eosinophil-associated recalcitrant pruritus

Latest Podcast

Cabazitaxel vs abiraterone or enzalutamide in poor prognosis metastatic CRPC

Professor Ronald de Wit, of the Erasmus MC Cancer Institute, Rotterdam, discusses the editorial he wrote with colleagues on the recent publication of Annala et al. They reported on a randomised, phase II study evaluating cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer.

Read the associated article
and
Read the associated article

Cabazitaxel vs abiraterone or enzalutamide in poor prognosis metastatic CRPC


PD-L1 expression as a biomarker in trials of cancer immunotherapy

Professor Ian Tannock discusses his editorial, with colleagues, published in the July issue of Annals of Oncology. He reviews the evidence relating to programmed death-ligand 1 (PD-L1) as a biomarker of effectiveness of immune checkpoint inhibitors and highlights problems in the design and reporting of immunotherapy trials that can lead to suboptimal treatment.

Read the associated article


Association of clinical factors and recent anticancer therapy with COVID-19 severity

Drs Ali Khaki and Petros Grivas discuss the recently published report from the COVID-19 and Cancer Consortium on the association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer.

Read the associated article


Zolbetuximab plus EOX vs. EOX alone for advanced CLDN18.2+ gastric and gastro-oesophageal cancer

Dr Ian Chau, of the Royal Marsden Hospital, London discusses the results of the FAST study, a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.

Read the associated article

Read the associated article


Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive NSCLC

Professor Johan Vansteenkiste, an associate Editor of Annals of Oncology, discusses the recent publication of Felip et al. that reports a study of the intracranial, and extracranial efficacy of lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI)in ALK-positive NSCLC that progressed on second-generation ALK TKIs.

Read the associated article

Read the associated article


Imatinib as an adjuvant in localized GIST

Professor Jean-Yves Blay, of the Centre Léon Bérard, Lyon, France, discusses the recent publication. in Annals of Oncology. of Casali et al. of a a randomized, open-label, multicenter phase III trial considering imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST).

Read the associated article


Postoperative ctDNA monitoring

Dr Yelena Janjigian of Memorial Sloan Kettering Cancer Center discusses her own and colleagues recent editorial in Annals of Oncology on a recent study in the journal by Ococks et al. on the use of liquid biopsy sampling for longitudinal tracking of esophageal carcinomas.

Read the associated article Postoperative ctDNA monitoring: a canary in a coalmine.

Read the associated article Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling.


Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma?

Professor Sumanta Pal discusses the recent editorial of himself and colleagues on the report of Albiges et al. on the safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma, published in the January 2021 issue of Annals of Oncology.

Read the full editorial here

Read the original report of Albiges et al. here


Overall survival with 3 or 6 months of adjuvant chemotherapy in the Italian TOSCA phase 3 trial

Dr Alberto Sobrero discusses the report of overall survival with 3 or 6 months of adjuvant chemotherapy in the Italian TOSCA (Three or Six Colon Adjuvant) phase 3 randomized trial recently published in Annals of Oncology.

Read associated article


Comparing survival outcomes of the APT trial with an external control from historical trials

Dr Eric Winer of the Dana-Farber Cancer Institute discusses a recent study published in Annals of Oncology that reported an analysis of the Adjuvant Paclitaxel and Trastuzumab (APT) trial. Although the APT trial has been adopted clinically, single-arm trials have limitations, and interest remains whether patients with small node-negative human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) would benefit from more intensive chemotherapy. This analysis explored whether external controls can contextualize single-arm studies to add to clinical decision making in the use of de-escalated therapy in patients with low-risk HER2-positive EBC.

Read associated article


Sacituzumab govitecan in previously treated HR+/HER2- metastatic breast cancer

Dr Aditya Bardia discusses a recent report in Annals of Oncology of the final results from a phase I/II, single-arm, basket trial of sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer. Sacituzumab govitecan (SG) is a Trop-2–directed antibody–drug conjugate.

Read associated article


Prof. Tony Mok discusses the overall survival analysis of the AURA3 trial

Prof. Tony Mok discusses the recent publication in Annals of Oncology: Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis


In our first ever Annals of Oncology podcast, Dan Haller talks to Tobi Arkenau, Executive Medical Director of the Sarah Cannon Research Institute, UK about his recently published research

Advertisement